190 related articles for article (PubMed ID: 8797205)
21. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.
Matsuno A; Nagashima T; Matsuura R; Tanaka H; Hirakawa M; Murakami M; Tamura A; Kirino T
Am J Clin Pathol; 1996 Dec; 106(6):776-81. PubMed ID: 8980354
[TBL] [Abstract][Full Text] [Related]
22. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
23. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
Abramovich CM; Prayson RA
Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K
Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483
[TBL] [Abstract][Full Text] [Related]
25. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study on the recurrence of meningiomas: correlating factors for the recurrence and therapeutic prognosis of meningiomas].
Miyagami M; Miyagi A; Kido G; Tsubokawa T
No Shinkei Geka; 1994 May; 22(5):421-8. PubMed ID: 8196827
[TBL] [Abstract][Full Text] [Related]
27. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
28. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
29. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
30. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
31. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
[TBL] [Abstract][Full Text] [Related]
32. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
Prayson RA
Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
34. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
35. [Ag-NORs, nucleus-nucleolus-associated antigens (Ki67, PCNA, P-105 and p-120): prognostic markers of meningioma recurrence].
Crafa P; Campanini N; Martella EM; Trabattoni G; Tedeschi F
Acta Biomed Ateneo Parmense; 1994; 65(5-6):297-308. PubMed ID: 8592922
[TBL] [Abstract][Full Text] [Related]
36. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
37. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
38. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
39. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
40. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
